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Abstract: 54 
The human 16p11.2 microdeletion is one of the most common gene copy number variations 55 
linked to autism, but the pathophysiology associated with this chromosomal abnormality is 56 
largely unknown. The 593-kb deletion contains the ERK1 gene and other genes that converge 57 
onto the ERK/MAP kinase pathway. Perturbations in ERK signaling are linked to a group of 58 
related neurodevelopmental disorders hallmarked by intellectual disability, including autism. We 59 
report that mice harboring the 16p11.2 deletion exhibit a paradoxical elevation of ERK activity, 60 
cortical cytoarchitecture abnormalities and behavioral deficits. Importantly, we show that 61 
treatment with a novel ERK pathway inhibitor during a critical period of brain development 62 
rescues the molecular, anatomical and behavioral deficits in the 16p11.2 deletion mice. The ERK 63 
inhibitor treatment administered to adult mice ameliorates a subset of these behavioral deficits. 64 
Our findings provide evidence for potential targeted therapeutic intervention in 16p11.2 deletion 65 
carriers. 66 
Significance Statement: 67 
 The ERK/MAPK pathway is genetically linked to autism spectrum disorders and other 68 
syndromes typified by intellectual disability. We provide direct evidence connecting the ERK/ 69 
MAP kinases to the developmental abnormalities in neurogenesis and cortical cytoarchitecture 70 
associated with the 16p11.2 chromosomal deletion. Most importantly, we demonstrate that 71 
treatment with a novel ERK specific inhibitor during development rescues aberrant cortical 72 
cytoarchitecture and  restores normal levels of cell cycle regulators during cortical neurogenesis.  73 
These treatments partially reverse the behavioral deficits observed in the 16p11.2del mouse 74 
model, including hyperactivity, memory as well as olfaction, and maternal behavior. We also 75 
report a rescue of a subset of these deficits upon treatment of adult 16p11.2del mice. These data 76 
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provide a strong rationale for therapeutic approaches to this disorder. 77 
Introduction: 78 
 Autism Spectrum Disorders (ASDs) are complex, highly heritable neurodevelopmental 79 
disorders affecting approximately 1 in 100 children. Copy number variations (CNVs) and other 80 
chromosomal rearrangements are associated with approximately 10-20% of ASDs. CNV of 81 
human chromosome 16p11.2 is one of the most common genetic linkages to autism and deletion 82 
of this region accounts for approximately 1% of ASDs (Levy et al., 2011). Individuals 83 
heterozygous for the 16p11.2 deletion exhibit a range of clinical symptoms including ASD, 84 
language impairment, intellectual disability (ID), anxiety, attention deficit hyperactivity disorder 85 
and epilepsy (Ghebranious et al., 2007; Zufferey et al., 2012; Hanson et al., 2015a). The human 86 
16p11.2 locus contains 27 genes, which includes the MAPK3 gene (encoding ERK1) and the 87 
Major Vault Protein gene (MVP), both of which converge onto the ERK/MAP kinase pathway 88 
(Kumar et al., 2007). 89 
 The extracellular signal-regulated kinases, ERK1 and ERK2,  are central elements of one 90 
of the most prominent intracellular signaling cascades, the Mitogen Activated Protein Kinase 91 
(MAPK) pathway. The ERKs play critical roles in brain development and synaptic plasticity 92 
(Sweatt, 2004) and are activated in response to a broad range of stimuli including growth factors, 93 
neurotransmitters, morphogens and transient increases in synaptic Ca2+ (Roskoski, 2012). 94 
Importantly, they are genetically linked to ASDs and other syndromes typified by ID (Marshall 95 
et al., 2008; Wen et al., 2016; Borrie et al., 2017; Mitra et al., 2017). Mutations in elements of 96 
the ERK/MAPK pathway alter the activity of the ERKs, resulting in a group of genetic disorders 97 
collectively known as “RASopathies”. These syndromes are typified by ID, developmental and 98 
language deficits, ASD and psychiatric disease (Tidyman and Rauen, 2009; Fasano and 99 
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Brambilla, 2011).  100 
 We have previously reported that a murine model of the 16p11.2 human microdeletion 101 
(16p11.2del) exhibits a reduction in brain size and perturbations in cortical 102 
cytoarchitecture,which are postulated to be due to impaired ERK-mediated regulation of neural 103 
progenitor proliferation (Newbern et al., 2008; Pucilowska et al., 2015). The 16p11.2del mice 104 
exhibit a paradoxical increase in ERK signaling coincident with aberrant cortical neurogenesis, 105 
ultimately resulting in behavioral deficits analogous to the 16p11.2 microdeletion carriers 106 
(Portmann et al., 2014; Hanson et al., 2015b). Therefore, we postulated that treatment with brain 107 
permeable Ras-ERK pathway inhibitors may correct the pathophysiology associated with the 108 
16p11.2 deletion. Recently, we have validated two novel cell permeable peptides (CPPs), RB1 109 
and RB3, that efficiently inhibit Ras-ERK signaling in the post-natal developing brain and rescue 110 
morphological impairments in a severe mouse model of RASopathies (Papale et al., 2017). In 111 
addition, the RB1 and RB3 peptides are able to block cocaine-mediated ERK activation and the 112 
associated behavioral response (Papale et al., 2016). 113 
 In this study, we report that prenatal treatment with cell permeant RB1/RB3 peptides 114 
rescues developmental deficits in neurogenesis in the embryo and subsequently restores normal 115 
neuronal numbers and cortical cytoarchitecture in the 16p11.2del mice. Specifically, we report 116 
restoration of hippocampal based memory function, anxiety, olfaction, maternal behavior as well 117 
as hyperactivity in the 16p11.2del mice. Furthermore, postnatal drug treatment of adult 118 
16p11.2del mice results in partial amelioration of the behavioral deficits, suggesting a broader 119 
window for pharmacologic intervention. To  assess the macroscale anatomical substrates affected 120 
by  the drug treatment, we used high-resolution morphoanatomical MRI mapping to show partial 121 
restoration of gray matter volume in ventral hippocampal and lateral septal regions, which we 122 
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found to be reduced in the 16p11.2del mice. We conclude that treatment with ERK pathway 123 
inhibitors may represent a potential therapeutic intervention in 16p11.2del carriers, as has been 124 
suggested for RASopathies (Tidyman and Rauen, 2009). This is the first example of the rescue 125 
of development abnormalities in this ASD model.  126 
 127 
Materials and Methods: 128 
Animals. A mouse line carrying a microdeletion on chromosome 7qF3, the syntenic region of 129 
human chromosome 16p11.2, was generated by A. Mills and purchased from Jackson Labs 130 
(Horev et al., 2011). This mouse line has been maintained on a fixed ratio, mixed (129/C57) 131 
background with large numbers of mice examined to minimize any genetic background-132 
associated variation. Embryonic and adult treatments were 5 days long and administered by sub-133 
cutaneous injections of ERK inhibitor resuspended in PBS at a dose of 10mg/kg. Pregnant dams 134 
were used with a plug date designated as 0.5 days.  135 
 136 
Drugs: RB1 and RB3 cell permeable peptides have been recently described (Papale et al., 2016). 137 
Briefly, RB1 was designed around residues 59-73 within the KIM sequence of the ERK-specific 138 
phosphatase MKP3 (Liu et al., 2006) that interacts with a docking motif required for interactions 139 
of ERK1/2 with both its regulators and substrates. RB3 was designed, using the MOE software 140 
package, (Molecular Operating Environment, version 10.10, Chemical Computing group, 141 
Montreal Canada, http://www.chemcomp.com) by aligning and superposing the CDC25 domain 142 
of Ras-GRF1 (Freedman et al., 2006) the published crystal structure of a ternary 143 
Ras:SOS:Ras*GDP complex (Sondermann et al., 2004) using the default settings. The 144 
interacting surface between the two proteins was then visually analyzed and the portion of the 145 
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CDC25 domain between residues 1173 to 1203 was selected for the preparation of the final 146 
peptide. RB1 (MGRKKRRQRRRPPQAPGIMLRRLQKGNLPVSRYPYDVPD), SCR RB1 147 
(MGRKKRRQRRRPPQALSLKRLRSRGMNRTSATQSRYPYD), RB3 148 
(GRKKRRQRRRPPCVPYLGMYLTDLVFIEEGTPNYTEDGLVN) and SCR RB3 149 
(GRKKRRQRRRPPCFEVYPDSGDYTYEGELNGTLMVVPTN) were custom synthesized by 150 
GENECUST EUROPE (Luxembourg).  151 
For in vivo experiments, batches of 200 mg, highly purified by high-performance liquid 152 
chromatography (HPLC) (≥ 95 %) with C-terminal amino acid (last) in D form and acetylated N-153 
Terminal (first) amino acid were used. The peptides were dissolved in PBS 1X and injected 10 154 
mg/kg (i.p.) (10 mg/kg each peptide) intraperitoneally.  155 
Sample preparation and MRI acquisition: High-resolution morpho-anatomical T2-weighted 156 
MR imaging of P90 ex vivo mouse brains was performed in paraformaldehyde fixed specimens. 157 
Standard sample preparation and MRI acquisition have been recently described in detail (Cutuli 158 
et al., 2016). Briefly, 16p11.2del mice and age-matched control littermates (treated with ERK 159 
inhibitor or vehicles) were deeply anesthetized and their brains were perfused in situ via cardiac 160 
perfusion. The perfusion was performed with phosphate buffered saline followed by 161 
paraformaldehyde (4% PFA; 100 ml). Both perfusion solutions included a gadolinium chelate 162 
(Prohance, Bracco, Milan) at a concentration of 10 and 5 mM, respectively, to shorten 163 
longitudinal relaxation times. Brains were imaged inside intact skulls to avoid post-extraction 164 
deformations. A multi-channel 7.0 Tesla MRI scanner (Bruker Biospin, Milan) was used to 165 
acquire anatomical images of the brain, using a 72 mm birdcage transmit coil and a custom-built 166 
saddle-shaped solenoid coil for signal reception, with the following imaging parameters: FLASH 167 
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3D sequence with TR = 17 ms, TE = 10 ms, alpha = 30°, matrix size of 260 × 180 × 180, field of 168 
view of 1.82 × 1.26 × 1.26 cm and voxel size of 0.07 mm (isotropic). 169 
Tensor Based Morphometry (TBM) automated anatomical labeling and structural 170 
covariance MRI network mapping. Inter-group morpho-anatomical differences in local 171 
volumes were mapped with TBM (Ashburner & Friston, 2000) using ANTs (Avants et al., 2009). 172 
The registration-based TBM procedure employed has been thoroughly described elsewhere 173 
(Pagani et al., 2016). First, all the high-resolution T2-weighted images were corrected for 174 
intensity non-uniformity and skull stripped to remove extra-brain tissue. A study-based template 175 
was then created aligning pre-processed images to a common reference space using affine and 176 
diffeomorphic registrations. Individual images of 16p11.2del and control mice (treated with ERK 177 
inhibitor or vehicle) were registered to the study-based template and the Jacobian determinants 178 
of the deformation fields were calculated at each voxel, giving the voxel's relative expansion or 179 
contraction in the space of the study-based template. Jacobian determinants were also normalized 180 
by the total intracranial volume to further eliminate overall brain volume variations. We 181 
measured non-normalized intracranial brain volume in all the four treatment groups at P90 . The 182 
results we obtained showed the presence of smaller brain volume in 16p11.2 mutants, a finding 183 
previously reported in mice modelling 16p11.2 deletion (Portmann et al., 2014). The treatment 184 
did not affect total intracranial volume in either WT or 16p11.2 mutants. The resulting maps 185 
were smoothed using a Gaussian kernel with a sigma of three voxel width and employed for 186 
voxel-wise statistics. Regional volume differences between 16p11.2del and control mice were 187 
mapped by fitting a GLM (t > 2.3) followed by a cluster correction using a significant cluster 188 
threshold of p = 0.01 (Worsley et al., 1992) as implemented in FSL. We also employed 189 
preprocessed images to independently calculate volumes of brain regions via automated 190 
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anatomical labeling (Pagani et al., 2016), using two neuroanatomically parcellated reference 191 
MRI atlases for cortical (Ullmann et al., 2013) and subcortical areas (Dorr et al., 2008).  192 
Behavioral analysis. Three-month-old male and female mice were utilized for standardized 193 
behavioral analyses including the elevated plus maze, open-field, novel object recognition, 194 
olfaction, maternal behavior and fear conditioning tests in order as stated. All tests were 195 
conducted in a designated behavior room during the light cycle between 9:00 A.M. and 6:00 196 
P.M. A maximum of 5 mice of mixed genotypes were housed together with ad libitum access to 197 
food and water with a 12 h light/dark cycle. All equipment was cleaned with 70% ethanol after 198 
each use to remove odor cues. The tester was blinded to the genotype of each animal. All tests 199 
were performed at the Case Western Reserve University Rodent Behavior Core. Three different 200 
cohorts (each with at least 50 mice divided to include both genotypes and treatment paradigms) 201 
were evaluated in three independent experiments. The data represents the pooled analysis of all 202 
three cohorts. 203 
The elevated plus maze: The maze consisted of two open and two closed arms crossing each 204 
other approximately 1 m above the floor. The maze was fitted with infrared grid and video 205 
tracking system (Med Associates Inc.). Individual test mice were placed in the center facing the 206 
open arm and their activity was recorded for 5 minutes. The % time spent in open and closed 207 
arms, the number of entries into each arm, number of head dips and frequency of 208 
urination/defecation were scored. 209 
Open field test: A box (40cm x 40cm) was placed in a dimly lit environment. EthoVision XT 5.0 210 
(Noldus) was used to digitally subdivide the box area into a 20 cm Å~ 20 cm center area and a 211 
periphery. The peripheral area was further divided into middle (inner 10 cm) and an outer area 212 
(outer 10 cm) to determine thigmotaxic behavior. Mice were placed in the center and allowed to 213 
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explore the area freely for 15 min. Locomotion parameters such as total distance, velocity, 214 
angular velocity and immobility were measured. Frequency and time duration in the center, 215 
periphery and outer area were recorded to determine anxiety-like behavior. In addition, data were 216 
nested into 5-min bins and distance moved during each of these 3 periods was recorded to 217 
evaluate habituation differences across groups. 218 
Novel Object: This assay was conducted 24 hours following the open field test in the same arena. 219 
Each subject mouse was placed in the chamber containing two identical objects and allowed free 220 
exploration for 10 minutes. Following a 3 hour delay, one of the familiar objects was replaced 221 
with a novel object and the test mice were returned to the same arena. The time spent sniffing 222 
each object was measured. Tester was blinded to the genotypes of tested mice. We scored and 223 
reported raw data of time spend sniffing novel (NO) vs. habituated object (HO) Mice that did not 224 
sniff either object and/or did not sniff for a total of 4 seconds were excluded from the final 225 
analysis. 226 
Olfactory Assay: Buried Food Retrieval. Mice were food deprived overnight and places in 227 
standard clean cages with normal cage bedding (3 cm). Mice were allowed to acclimate for 5 228 
minutes, then were removed to another clean cage at which point a uniform piece of food (Teddy 229 
Graham) was placed in a random corner under approximately 1cm of normal bedding. Next, each 230 
mouse was returned to its cage and the time to retrieve the food source (latency) was recorded.  231 
Contexual and Cued Fear Conditioning: Fear conditioning test was conducted as the last 232 
behavioral test in the series of all behavioral assesments. Experiments utilized two standard 233 
conditioning chambers, each housed in an isolation cubicle and equipped with a stainless-steel 234 
grid floor connected to a solid-state shock scrambler. Each scrambler delivered an electronic 235 
constant-current shock source that was controlled via an interface connected to a Windows XP 236 
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computer running FreezeFrame software (Coulbourn Instruments, Allentown, PA). A digital 237 
camera was mounted to the side of each chamber, and video signals were sent to the same 238 
computer for analysis. During training, mice were placed in the conditioning chamber for 12 min 239 
and then received four footshocks (cond. stimulus: 85 dB sound at 2800 Hz for 30 sec.; 240 
unconditioned stimulus (US: 0.56mA). Retention test was performed 18 hrs later for 5 minutes in 241 
the absence of a shock. 242 
Analysis of progenitor proliferation. Mice received a single intraperitoneal injection of BrdU 243 
(50 mg/kg, Sigma-Aldrich B5002) at E14.5 and sacrificed exactly 30 minutes later (veh.treated: 244 
nWT = 8, nDel=6; inh.treated: nWT = 9, nDel=9). Sections were immunostained with anti-BrdU 245 
antibody, (rat-anti-BrdU; 1:100, Abcam), or mouse anti-BrdU (1:100, BD Biosciences). The 246 
number of BrdU+ cells per cortical sections (proliferative fraction) was established using 247 
stereological technique and all positive cells within a 100µm segment along the ventricular 248 
surface, extending from the ventricle to the pial surface, were counted. All data collection was 249 
blinded to the genotype and randomized. In embryonic brains all analyses were performed at the 250 
rostro-caudal axis of fully emerged ganglionic eminences, (LGE as well as MGE). These 251 
structures as well as the presence of choroid plexus were noted and the images were taken just 252 
above the pallial/subpallial boundary in the VZ as well dorso-medial area of the VZ. In adult 253 
mice we evaluated BrdU staining in two different areas; 1) above the pallial/subpallial boundary 254 
(dorsolateral), the other (2) at the level of dorsomedial cortex. For postnatal analyses we 255 
evaluated both motor and somatosensory cortex. 256 
Microscopy and image analysis. All sections were imaged using a Zeiss LSM 510 confocal 257 
laser microscope equipped with argon and helium–neon lasers and analyzed with LCS confocal 258 
software, Prism and Photoshop (Adobe). All counts were performed on blinded sections and 259 
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two-way ANOVA with Bonferroni post hoc was used to establish statistical significance for each 260 
experiment. 261 
Western analysis. Cortices were dissected from  E14.5 embryos and washed with ice-cold 262 
HBSS. The lysates were sonicated in lysis buffer (20 mM Tris, pH 7.5,150 mM NaCl, 1% NP-263 
40, 10% glycerol, 1 mM EDTA, 1.5 mM MgCl2, 20 mM NaF, and 20 mM β-glycerophosphate) 264 
in the presence of protease inhibitors (1 μg/ml leupeptin, 1 μg/ml aprotinin, 1 mM PMSF, and 265 
1 mM Na3VO4). Samples were centrifuged, and protein concentrations were established with 266 
bicinchoninic acid assay (Pierce) using a BSA standard. Equal amounts of protein were boiled in 267 
sample buffer, separated on SDS-PAGE gels, and transferred to Immobilon-P polyvinylidene 268 
difluoride membranes (Millipore). Membranes were blocked in 3% BSA (or 5% skim-milk) in 269 
TBS and 0.1% Tween 20 (TBS-T) for 2 h at room temperature and incubated with primary 270 
antibodies overnight at 4°C. The primary antibodies used were: rabbit anti-pERK (Cell 271 
Signaling, 1:1000), mouse anti-ERK2 (BD Biosciences Discovery Labware, 1:3000), mouse 272 
anti-ERK1 (Zymed Laboratories, 1:1000), anti-CoxIV and (1:3000; Cell Signaling). Membranes 273 
were washed with TBS-T, incubated with HRP-conjugated secondary antibodies: goat anti-274 
mouse or anti-rabbit (1:5000; GE Healthcare) in TBS-T with 5% milk for 2 h at room 275 
temperature. Detection was performed using Millipore chemiluminescence using BioMax MR 276 
X-ray film (Eastman Kodak). Densitometry was performed using Adobe Photoshop histogram 277 
function, and statistical analysis was done with GraphPad Prism software. 278 
ELISA. The oxytocin (OT) Elisa was performed using ENZO Oxytocin kit (Prod.No. ADI-901-279 
153A) according to the manufactures instructions. Whole brain homogenates of P90 WT and 280 
16p11.2del  brains were used and the calometric readout was reported in pg/ml.  281 
Immunohistochemistry. The E14.5 brains were dissected in cold PBS and fixed by immersion 282 
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in 4% paraformaldehyde (PFA) for 1hour or overnight at 4o C. P10 and adult mouse brains were 283 
fixed in 4% PFA/1X PBS at 4°C overnight and serially incubated in 10, 20 and 30% sucrose. 284 
The brains were sectioned (10 μm), then rehydrated in PBS for 10 min. Antigen retrieval using 285 
1X Reveal Decloaker (Biocare) was performed for 10 minutes at 95°C. Sections were blocked in 286 
10% (embryonic) and 2% (postnatal) normal goat or donkey serum for 1 hour at room 287 
temperature with 0.1% (vol/vol) Triton X-100 in PBS. Slides were incubated with primary 288 
antibodies overnight at 4°C, rinsed with PBS and incubated with corresponding secondary 289 
antibodies for 1-2 hours at room temperature. The primary antibodies used were as follows: 290 
polyclonal rabbit anti-pERK (Cell Signaling, 1:100); rabbit polyclonal anti-Pax6 (Covance, 291 
1:300); mouse anti-PH3 (Upstate, 1:250); rabbit anti-PH3 (Upstate, 1;500); rabbit anti-Tbr1 292 
(Chemicon,1:1000); rabbit anti-Tbr2 (1:300); chicken anti-Tbr2 (1:250); goat anti-Brn1 (Santa 293 
Cruz Biotechnology, 1:50), rat anti-Ctip2 (Abcam,1:500); rabbit anti-Cux1 (Santa Cruz, 1:100) 294 
and mouse anti-SatB2 (Abcam, 1:100). Secondary antibodies used were Alexa Fluor 488 295 
(1:1000), 546 or 593 (1:1000) conjugated to goat or donkey anti-mouse, anti-rabbit or anti-goat 296 
(Invitrogen). DNA was stained with 4′ ,6′ -diamidino-2-phenylindole (DAPI) for 5 min 297 
(DAPI, Molecular Probes).  Immunohistochemical staining was performed on all 4 groups 298 
simultaneously.  299 
Embryonic Brains. Anatomically matched sections of littermate WT and mutant mice were 300 
analyzed. At least 3 consecutive sections per animal were analyzed alongside the mid-rostro-301 
caudal axis of the dorsal telencephalon. Embryonic coronal sections were evaluated at the level 302 
of the ganglionic eminences and analyzed by counting all cells in standard 100μm bins extending 303 
from the ventricle to the pial surface. Quantification was performed blind to genotype as 304 
previously described (Glickstein et al., 2009). Three to four litters were examined per 305 
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experiment. 306 
Adult Brains. We counted at least three consecutive tissue slices per slide and at least four slides 307 
per animal. In postnatal brains, coronal sections were used to count cells in 400μm boxes in 308 
somatosensory and motor cortex. Slides were picked at random and the investigator was blinded 309 
to genotypes and treatments. All data from a single experiment, incorporating all 4 experimental 310 
groups, was averaged. The number of mice evaluated is indicated in figure legends, with three to 311 
four litters examined per experiment. 312 
Statistical Analysis. All data analyzed followed normal distribution according to the 313 
Kolmogorov-Smirnov test. Statistical significance was determined using two-way ANOVA 314 
followed by Bonferroni’s post hoc test for multiple comparisons. Data analysis was performed 315 
using GraphPad Prism and presented as means ± s.e.m.  316 
 All experiments in this study were blinded and randomized. All mice bred for the 317 
experiments were utilized for preplanned experiments and randomized to experimental groups. 318 
Visibly sick animals were excluded before data collection and analysis. Data were collected, 319 
processed and analyzed randomly. The experimental design, treatments and handling of mice 320 
were identical across experiments. Littermates were used as controls with multiple litters (3-4) 321 
examined per experiments. All mice (including the MRI study) were bred in the Case Western 322 
Reserve Animal Core. 323 
Results:  324 
Pharmacological Normalization of ERK Activity with an ERK Pathway Inhibitor in 325 
16p11.2del Mice.   326 
 In order to test our hypothesis that there are ERK-mediated pathologic processes 327 
occurring in the 16p11.2del mice, we took advantage of two recently developed brain penetrant 328 
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peptides, RB1/RB3, which act in concert to attenuate Ras-ERK activity in the brain(Papale et al., 329 
2016, 2017). These brain penetrant peptides exhibit IC50 values in the micromolar range (Papale 330 
et al., 2016). Importantly, these peptides have been successfully used in vivo for early post-natal 331 
developmental treatments, manifesting a remarkable high degree of tolerability and low toxicity. 332 
Based on these promising results, we treated with the RB1/RB3 mix (hereafter termed ‘ERK 333 
Inhibitor’) the pregnant 16p11.2del carrier dams for 5 consecutive days starting at E10.5, 334 
encompassing a critical period of cortical neurogenesis. We observed that the enhanced ERK 335 
activity in dorsomedial cortex of 16p11.2del mice at E14.5 was normalized in the inhibitor-336 
treated mice (Fig. 1a,b,c). At E14.5 two-way ANOVA analysis of ERK1 activity showed a 337 
significant effect with respect to genotype (F[1,59]=21.7, p<0.0001) and inhibitor treatment 338 
(F[1,59]=10.12, p=0.002), but with an interaction between both variables (F[1,59]=4.05, 339 
p=0.049). Bonferonni post-hoc analysis showed a 2-fold increase in ERK1 activity (p<0.0001) in 340 
the vehicle treated 16p11.2del mice compared to vehicle treated WT mice that normalized to WT 341 
levels following inhibitor treatment. Similarly, ERK2 activity was also significantly affected by 342 
both genotype (F[1,77]=4.31, p=0.041) and inhibitor treatment (F[1,77]=6.76, p=0.011) when 343 
analyzed by two-way ANOVA, however a significant interaction between genotype and drug 344 
treatment was present (F[1,77]=5.08, p=0.027). A Bonferonni post-hoc analysis showed a 49% 345 
(p=0.017) increase in ERK2 activity in the vehicle treated 16p11.2del mice compared to vehicle 346 
treated WT mice that normalized to WT levels with inhibitor treatment. Importantly, total ERK1 347 
levels were reduced in the 16p11.2del mice in both vehicle and inhibitor treated animals, with a 348 
significant genotype effect observed by two-way ANOVA (p<0.0001). We observed significant 349 
interactions between the inhibitor and genotype because, interestingly, the dose of the ERK 350 
inhibitor (10 mg/kg, i.p.) used in our studies did not alter ERK activity in the WT littermates. In 351 
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addition, when ERK1/2 activity was analyzed in P10 embryonically treated mice (Fig. 1d,e), 352 
there was an inhibitor effect (pERK1:p=0.005, pERK2:p=0.017) by two-way ANOVA, with a 353 
Bonferonni post-hoc analysis showing a 75% (p<0.01) and 62% (p<0.01) increase in ERK1 and 354 
ERK2, respectively, in the 16p11.2del vehicle treated mice that normalized to WT levels. Thus, a 355 
prenatal treatment of embryonic mice resulted in abrogation of abnormal ERK hyperactivity in 356 
the developing cortex when examined at E14.5 (Fig. 1b,c) or postnatally at P10 (Fig. 1d, e).  357 
 358 
ERK Inhibitor Treatment Rescues Embryonic and Postnatal Cortical Defects in the 359 
16p11.2del Mice.  360 
 Next, we investigated whether the embryonic treatment with the ERK pathway inhibitor 361 
could correct aberrant progenitor proliferation dynamics in the developing cortex (Fig. 2 a-b) and 362 
rescue deficits in cortical neurogenesis (Fig. 2c-d). We evaluated the number of proliferating, 363 
BrdU+ progenitors following a single, 30 min IP BrdU injection at E14.5. A 2-way ANOVA 364 
analysis showed no genotype or inhibitor effect, but Bonferroni post-hoc analysis showed a 30% 365 
increase (p<0.05) in BrdU+ progenitors in the vehicle treated 16p11.2del mice compared to 366 
vehicle treated WT mice. This increase in progenitor proliferation was abrogated in ERK 367 
inhibitor treated 16p11.2del mice and returned to WT levels (Fig.2a). Furthermore, western blot 368 
analysis and immunohistochemistry (IHC) demonstrate that the number of Tbr2+ intermediate 369 
progenitor cells (IPCs) residing in the SVZ can be restored to normal levels after the inhibitor 370 
treatment (Fig. 2b). Western blot analysis of Tbr2 by two-way ANOVA showed a genotype and 371 
inhibitor interaction, but post-hoc analysis revealed a 30% decrease in Tbr2 levels (p<0.0001) in 372 
the vehicle 16p11.2del mice, which returned to normal following treatment, when compared to 373 
vehicle WT mice. This correlated with a 37% decrease (post-hoc Bonferroni, p=0.0012) in the 374 
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number of Tbr2+ cells by IHC in the vehicle treated 16p11.2del mice, that corrected to WT 375 
levels in the inhibitor treated mice when compared to vehicle WT animals (2-way ANOVA 376 
showed significant inhibitor and genotype interaction). Additionally, using western analysis and 377 
IHC we also show that treatment with ERK inhibitor ameliorates the aberrant elevation of the 378 
number of early born cortical neurons marked by Ctip2+ and Tbr1+ that populate cortical layer 379 
V and VI, respectively (Fig.2c-d). Again 2-way ANOVA analyses of IHC and western blots of 380 
Tbr1 and Ctip2 showed interactions between genotype and inhibitor, but the post-hoc Bonferroni 381 
analysis showed a 50% increase in Ctip2 levels (p=0.012) and a 30% increase in Ctip2+ cells by 382 
IHC (p=0.0005) in the 16p11.2del vehicle treated mice, which returned to WT levels when 383 
compared to WT vehicle treated animals. Tbr1 analysis showed a 35% increased in Tbr1 protein 384 
levels (p=0.038), and a 20% increase in Tbr1+ cells via IHC (p=0.025) in the 16p11.2del vehicle 385 
treated mice that returned to WT levels in the inhibitor treated mice, when compared to WT 386 
vehicle treated animals.  387 
 Next, we tested whether prenatal ERK inhibitor treatment resulted in permanent rescue of 388 
cortical cytoarchitecture defects by evaluation of postnatal mice at P2. We show that the number 389 
of Brn1+ and Satb2+ layer II-III pyramidal neurons is restored to normal levels after prenatal 390 
ERK inhibitor treatment (Fig.3a-b). These are cortico-cortical connections, some of which 391 
project to contralateral hemisphere across the corpus callosum (O’Rourke et al., 1995). Satb2 392 
analysis shows significant genotype (p=0.048) and treatment effect (p=0.013) by 2-way 393 
ANOVA. Post-hoc analysis shows significant 13% reduction in Satb2+ cells in vehicle deletion 394 
animals compared to WT vehicle (p=0.03), which is abrogated with inhibitor treatment of 395 
deletion animals, which show Satb2+ cells similar to vehicle WT animals and significant 396 
increase when compared to vehicle treated 16p11.2del mice (p=0.01). Brn1 analysis shows no 397 
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genotype or treatment effect by 2-way ANOVA, but post-hoc analysis shows decrease Brn1+ 398 
cells in vehicle treated 16p11.2del mice compared to WT vehicle-treated animals (p<0.05), but 399 
inhibitor treated 16p11.2del mice show no difference in Brn1+ cells compared to WT vehicle-400 
treated animals.  401 
 Analysis of Tbr1 cells by 2-way ANOVA showed an interaction between genotype and 402 
inhibitor treatment, but post-hoc analysis of vehicle treated 16p11.2del animals showed a 25% 403 
increase in Tbr1+ cells compared to vehicle treated  WT animals (post-hoc Bonferroni, 404 
p=0.0075), which is rescued with treatment of 16p11.2del  animals with ERK inhibitor (Fig. 3d), 405 
consistent with the effect of the inhibitor on these neurons observed at E14.5 (Fig.2d). The 406 
number of Ctip2+ layer V neurons, known to project to sub-cortical targets including the 407 
thalamus, midbrain, pons and spinal cord, is increased during mid-neurogenesis, but decreased 408 
postnatally in vehicle 16p11.2del mice when compared to WT vehicle treated mice (post-hoc 409 
Bonferroni, p =0.014) and normalized by inhibitor treatment of 16p11.2del  animals, which have 410 
more Ctip2+ neurons compared to vehicle 16p11.2del  animals (p=0.033) and no difference 411 
compared to WT vehicle  treated animals (Fig.2c, 3c). It is unknown why these projection 412 
neurons are ultimately lost in the 16p11.2del mice. These data demonstrate the developmental 413 
rescue of cortical deficits in progenitor proliferation and neurogenesis in the 16p11.2del after 414 
pharmacological intervention with the ERK pathway inhibitor. 415 
 416 
ERK inhibitor treatment normalizes levels of the cell cycle regulators p27 Kip1 and cyclin 417 
D1.  418 
 To examine whether the aberrant generation of cortical neurons is due to deficits in cell 419 
cycle dynamics, we examined two critical cell cycle regulators: p27 Kip1 and cyclin D1 (Fig.4), 420 
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which are directly regulated by ERK signaling and play an important role in progenitor 421 
proliferation (Calegari and Huttner, 2003; Dehay and Kennedy, 2007; Lange et al., 2009; 422 
Pucilowska et al., 2012). We performed IHC and western blot analysis and observed a significant 423 
decrease in p27Kip1 protein levels in the 16p11.2del cortex, consistent with our previous 424 
observations. Two-way ANOVA analysis of p27 kip1 showed no genotype or inhibitor effect, but 425 
post-hoc analysis showed a 31% decrease (p<0.01) in p27kip1 levels in the 16p11.2del vehicle 426 
treated mice compared to the WT vehicle treated animals, which normalized to 92% of the 427 
vehicle WT level after inhibitor treatment (Fig. 4b’-b”).  When cyclin D1 levels were analyzed 428 
by two-way ANOVA, there was only a inhibitor effect (F[1,46],p<0.0001), but no genotype 429 
effect, with significant decrease in cyclin D1 in the inhibitor treated 16p11.2del mice (p<0.001) 430 
compared to the vehicle treated 16p11.2del mice (Fig.4a-a”). These data show that the 431 
16p11.2del mice exhibit ERK dependent changes in cell-cycle dynamics of neural progenitor 432 
cells that are ameliorated with the prenatal ERK inhibitor treatment.  433 
 434 
ERK inhibitor treatment partially rescues hippocampal and septal morphoanatomical 435 
abnormalities in  16p11.2del mice         436 
 To determine whether ERK inhibitor treatment would affect macroscale brain 437 
morphoanatomy in  16p11.2del mice, we applied voxelwise Tensor Based Morphometry (TBM) 438 
and automated anatomical labeling to high-resolution MRI brain scans (Pagani et al., 2016). 439 
Consistent with previous reports (Horev et al., 2011), 16p11.del mice showed increases in the 440 
relative volume of the hypothalamus, superior colliculus and periaqueductal grey when 441 
compared to control (WT) mice (Fig. 5a). Voxelwise TBM mapping also revealed foci of 442 
decreased volume in ventral hippocampal, amygdalar, entorhinal and lateral septal areas in 443 
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16p11.2del mice when compared to WT controls (Fig.5a). Importantly, treatment with the ERK 444 
inhibitor partially-rescued ventral hippocampal and lateral septal volume in 16p11.2del mice 445 
when compared to vehicle treated controls (Fig. 5b-c).  Interestingly, the ventral hippocampus is 446 
a region where pERK is highly expressed during mid-neurogenesis and a key substrate for 447 
anxiety-related behavior (Kjelstrup et al., 2002; Maren and Holt, 2004) which these mice exhibit.  448 
 449 
Rescue of behavioral deficits in 16p11.2del mice after prenatal ERK inhibitor treatment.  450 
 We, as well as others, have previously shown that the 16p11.2del mice are smaller than 451 
their WT littermates (Horev et al., 2011; Portmann et al., 2014; Pucilowska et al., 2015; Tidyman 452 
and Rauen, 2016). We report that prenatal treatment with ERK pathway inhibitor restored 453 
normal body weight in the 16p11.2del mice when examined at 3 months of age (WT vehicle 454 
treated: 35.015g; 16p11.2del vehicle treated: 25.352g;  16p11.2del  inhibitor-treated: 29.396g). 455 
 The 16p11.2 del mice are reported to exhibit many behavioral deficits (Horev et al., 456 
2011; Portmann et al., 2014; Pucilowska et al., 2015; Yang et al., 2015). We tested the 457 
16p11.2del and WT control mice in a number of standard behavioral paradigms that are altered 458 
by the 16p11.2 deletion. Specifically, we assayed open field to evaluate hyperactivity and 459 
anxiety-like behaviors, novel object and fear conditioning to examine hippocampal dependent 460 
memory, elevated-plus maze (EPM) to test anxiety as well as maternal behavior and olfaction. 461 
We evaluated three large cohorts (n=30/genotype) of 3 month-old male mice (except for 462 
maternal behavior and olfaction). Data was analyzed by 2-way ANOVA, but unless otherwise 463 
indicated, significant interaction occurred between the genotype and inhibitor treatment, which 464 
resulted in reliance on post-hoc analysis to show genotype or inhibitor effects.  465 
 We first conducted the EMP test, where examining entries into the closed arm, the post-466 
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hoc analysis showed fewer closed arm entries by vehicle 16p11.2del  mice compared to vehicle 467 
WT mice (p<0.05), which was rescued in the inhibitor treated deletion animals who showed 468 
more closed arm entries compared to vehicle treated 16p11.2del  animals (p<0.05) and no 469 
difference with vehicle treated WT animals. Furthermore, we observed statistical significance in 470 
time spent in the open arm (p<0.05), which was only partially rescued by inhibitor treatment 471 
with no genotype or inhibitor effect by 2-way ANOVA. We also noted an increase in open arm 472 
immobility, indicating freezing behavior (6a).  In the open field test (Fig. 6b), we first examined 473 
level of activity which showed that the 16p11.2del mice did not explore the field as much as the 474 
WT mice. 2-way ANOVA analysis of total distance travelled showed significant genotype 475 
(F[1,76], p=0.005) and drug effect (F[1,76], p=0.02) with no interaction, although post-hoc tests 476 
did not show significance between vehicle WT and 16p11.2del  animals or vehicle and inhibitor 477 
treated 16p11.2del  animals. However, in the open field test (Fig. 6b), we observed that vehicle 478 
treated 16p11.2del  mice spent more time in the center compared to vehicle treated WT mice 479 
(post-hoc Bonferroni, p<0.01), which was rescued by ERK inhibitor treatment, as inhibitor 480 
treated 16p11.2del  mice were similar to vehicle treated WT mice and spent less time in the 481 
center compared to the vehicle treated 16p11.2del mice (post-hoc Bonferroni, p<0.05). 482 
Interestingly, total distance travelled was also increased in the vehicle treated 16p11.2del  mice 483 
compared to vehicle treated WT mice (post-hoc Bonferroni, p<0.05), which again normalized 484 
with inhibitor treatment of 16p11.2del  mice, who showed significant decreased in distance 485 
travelled compared to vehicle treated 16p11.2del n animals (p<0.05) and no difference with 486 
vehicle treated WT animals.  487 
 Contextual fear conditioning showed significantly higher freezing percentage in the 488 
vehicle treated 16p11.2del  mice compared to the vehicle treated WT cohort (post-hoc 489 
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Bonferroni, p<0.01) indicating impaired contextual memory (Fig. 6c). This is improved by 490 
treatment of the 16p11.2del  animals with the ERK inhibitor, which show no difference 491 
compared to vehicle treated WT animals, but no significant difference was observed between 492 
vehicle and inhibitor treated 16p11.2del  animals. 493 
 Novel object recognition (NOR) did not reveal a significant genotype or inhibitor effect 494 
in post-hoc analysis, but a trend showing impaired NOR in vehicle treated 16p11.2del  compared 495 
to vehicle treated WT mice (p=0.16), which improved with inhibitor treatment of 16p11.2del  496 
mice, who showed a trend toward improvement in NOR compared to vehicle treated 16p11.2del  497 
mice (p=0.11) (Fig 6d). 498 
 Both male and female 16p11.2del mice exhibited a significantly higher acuity in their 499 
sense of smell compared to the WT mice (post-hoc Bonferroni, p<0.01), which was attenuated 500 
after the treatment (Fig 6f). Inhibitor treated 16p11.2del  mice showed significant attenuation in 501 
olfaction compared to vehicle treated 16p11.2del  mice (p<0.0001).   502 
 Additionally, females showed heightened maternal response, as measured in a pup 503 
retrieval assay that was reduced following ERK inhibitor treatment (Fig. 6e). Vehicle treated 504 
16p11.2del  animals showed decreased latencies to retrieving all pups compared to vehicle 505 
treated WT animals (pup1: p<0.01, pup2: p<0.01, pup3: p<0.001). This effect was reverted with 506 
treatment of 16p11.2del  animals with inhibitor as no difference in latencies was observed when 507 
compared to WT vehicle treated animals (post-hoc Bonferroni, p<0.01). 508 
 Altogether, the above evidence supports the notion that an early pharmacological 509 
intervention targeting ERK signaling in 16p11.2del mice is sufficient to reverse some of the 510 
behavioral alterations found in this model of ASD. 511 
  512 
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Postnatal treatment with ERK inhibitor partially restores behavioral deficits of adult 513 
16p11.2del mice.  514 
 We next questioned whether any of the behavioral deficits could be improved by ERK 515 
inhibitor treatment in adult mice. Therefore, we treated 3 month-old WT and 16p11.2del male 516 
mice with ERK inhibitor for 5 consecutive days at P90.  517 
 In the elevated plus maze, we observed that vehicle treated 16p11.2del animals spent 518 
more time in the open arm compare to the vehicle WT cohort (Fig. 7a; post-hoc Bonferroni, p 519 
<0.05). This effect was abrogated in ERK inhibitor treated 16p11.2del animals as no difference 520 
in open arm time was observed when compared to vehicle treated WT animals (2-way ANOVA 521 
showed significant interaction between genotype and inhibitor treatment). In the open field test, 522 
we did not observe significant genotype effects between vehicle treated 16p11.2del and WT 523 
animals in post-hoc analysis, however, we did observe a trend toward more open entries in 524 
vehicle 16p11.2 del animals compared to WT (Fig. 7b). In addition, treatment of 16p11.2del 525 
animals with the ERK inhibitor showed significant reduction in entries into the center of the field 526 
compared to vehicle treated 16p11.2del animals (post-hoc Bonferroni, p<0.01). Although the 527 
adult treated mice did not achieve statistical significance in the olfactory test, there was a trend 528 
toward heightened acuity in the 16p11.2del mice, which was at least partially recovered after the 529 
inhibitor treatment (Fig. 7d). Together our data suggests that post-natal treatment with the ERK 530 
inhibitor may result in partial rescue of some of the behavioral deficits seen in the 16p11.2del 531 
mice.   532 
 Since other models linked to ASDs and the ERK pathway show aberrant levels of 533 
oxytocin (Hollander et al., 2007), we examined 3 month-old male mice and show that levels of 534 
oxytocin are elevated in the 16p11.2del male mice and importantly can be restored to normal 535 
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after inhibitor treatment (post-hoc Bonferroni, p<0.01)( Fig.7c). We observed by 2-way ANOVA 536 
a significant genotype (F (1, 24) = 6.132, p0.0207) and drug effect (F (1, 24) = 8.712, p=0.0070) 537 
and significant interaction F (1, 24) = 4.884, p=0.0369. 538 
 The 16p11.2del mice do not exhibit typical social deficits that are common among other 539 
models of ASDs as well as 16p11.2del patients, thus, the enhanced oxytocin levels, which 540 
normally augment social interactions, could be masking the social impairment in these mice. 541 
Further studies using oxytocin inhibitors could clarify this phenomenon. 542 
Discussion:  543 
ERK/MAPK pathway as a potential target for ASD therapy 544 
 The ERK/MAPK pathway has been extensively studied and found to play pivotal roles in 545 
neural development as well as in learning, memory, synaptic plasticity and spine dynamics 546 
(Thomas and Huganir, 2004). The functional importance of signaling through this pathway is 547 
also reflected in the effects of activating mutations that alter the activity of the ERK1/2 kinases 548 
and result in a constellation of syndromic and non syndromic neurodevelopmental disorders, 549 
including the RASopathies and the associated intellectual disability (Tidyman and Rauen, 2016; 550 
Borrie et al., 2017).  551 
 It has recently been appreciated that some forms of ASD are also associated with 552 
perturbations of several intracellular signaling cascades, including the Ras-ERK and the 553 
mTORC1 pathways (Kalkman, 2012; Adviento et al., 2014; Borrie et al., 2017). In addition to 554 
genetic linkages, pathway network analyses point to a convergence of a wide range of 555 
abnormalities associated with autism onto a few salient pathways, prominent amongst these is 556 
the ERK/MAPK pathway (Wen et al., 2016; Mitra et al., 2017). Importantly, many ASD mouse 557 
models with genetic alterations of Mecp2, FMR1, NF1, Syngap as well as, BTBR and 558 
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16p11.2del exhibit aberrant ERK signaling (Liang et al., 2010; Osterweil et al., 2010, 2013; 559 
Hamdan et al., 2011; Bhakar et al., 2012; Wang et al., 2013; Golzio et al., 2012; Kelleher III et 560 
al., 2012; Wang et al., 2012; Faridar et al., 2014; Pucilowska et al., 2015). These data argue that 561 
the abnormal ERK activity in the brain is central to pathology of many ASDs.  562 
 We and others have previously shown that the genetic deletion of the 16p11.2 interval 563 
results in a paradoxical increase in ERK activity that is associated with aberrant neural 564 
progenitor proliferation which leads to dysregulation in the number of neurons generated within 565 
the cortex (Pucilowska et al., 2015) and subcortical structures (Portmann et al., 2014; Grissom et 566 
al., 2018). This results in altered volumes of the cortical lamina and subcortical nuclei.  567 
 These studies raise the possibility that ERK inhibitors can be used to normalize their 568 
activity and have therapeutic efficacy in 16p11.2 deletion carriers. We reasoned that 569 
normalization of ERK activity might rescue the CNS phenotypes observed in the 16p11.2del 570 
mice. It is noteworthy that Papale et al., utilizing the newly developed ERK pathway inhibitor 571 
peptides, have recently shown that the treatment ameliorates defective synaptogenesis in a 572 
genetic model of RASopathy (Papale et al., 2017). Moreover, they have shown its effectiveness 573 
of ERK pathway inhibition by treatment of murine models of cocaine addiction, suppressing the 574 
behavioral phenotypes (Papale et al., 2016).  575 
ERK inhibitor suppresses the increase in ERK activity in 16p11.2del mice  576 
 The 16p11.2del mice exhibit paradoxical increase in ERK activity in both the developing 577 
and mature brain. This finding was unexpected given that the deletion removes the Mapk3 gene 578 
encoding ERK1. The biological basis of dysregulation of the ERK pathway in this model is 579 
unknown. However, we and others have previously postulated that ERK1 acts a negative 580 
regulator of  ERK2 (Mazzucchelli et al., 2002; Vantaggiato et al., 2006; Fasano and Brambilla, 581 
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2011; Trabalzini and Retta, 2014) and our findings are consistent with this hypothesis but basis 582 
of the elevated ERK1 activity  remains unclear. We found that basal ERK activity in wildtype 583 
mice was not altered by drug treatment and this likely represents the intrinsic basal activity of the 584 
ERKs that is independent of upstream regulators, and thus not subject to further inhibition by the 585 
RB1 peptide.  586 
 The 16p11.2 deletion contains 27 genes. Mice lacking ERK1or ERK2 do not recapitulate 587 
the entire range of defects observed in the 16p11.2del mice, implicating the contribution of other 588 
genes within this interval to the ASD phenotypes. Importantly, at least two other genes (MVP 589 
and KCTD13) within the deleted region converge onto the MAPK pathway and affect cell 590 
proliferation, mGluR5 signaling and protein turnover (Liang et al., 2010; Golzio et al., 2012; 591 
Tian et al., 2015). This suggests that multiple genes within the deletion interval converge on the 592 
ERK/MAPK pathway resulting in an overall increase in ERK activity.   593 
 594 
ERK inhibitor rescues cortical defects in 16p11.2del mice 595 
 We provide mechanism-based evidence showing that treatment with ERK inhibitors 596 
during the peak of neurogenesis rescues the structural and behavioral deficits observed in the 597 
16p11.2del mice. Specifically, we found that the aberrant generation of cortical neurons was 598 
restored to normal levels owing to normalization of neurogenesis following developmental drug 599 
treatment. This was secondary to the ERK- dependent modulation of potent cell cycle regulators 600 
cyclin D1 and p27Kip1. The retention of normal numbers of neural progenitors during critical 601 
neurogenic period allowed for generation of appropriate numbers of cells populating cortical 602 
lamina as well as normal circuitry. Importantly, we corraborated our molecular and biochemical 603 
findings with MRI data showing partial reversal of volumetric changes to the ventral 604 
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hippocampus and lateral septum. It is of interest to note that the MRI analyses showed that the 605 
ERK inhibitor treatment did not rescue all of the anatomical abnormalities in the brain, which 606 
may be related to a short treatment window implemented in this study and the temporal variation 607 
in neurogenesis between different brain regions. 608 
ERK Inhibitor rescues behavioral deficits in 16p11.2del mice 609 
 One of the most striking findings from this study is the reversal of a wide range of 610 
behavioral deficits that arise from the 16p11.2 deletion. Our data shows the first developmental 611 
rescue of ASD associated phenotypes in the 16p11.2del mouse model. The data from the 612 
elevated plus maze and open field did show statistical significance for changes in anxiety-like 613 
behaviors but not as strong as in previous studies, which is possibly due to increased sample size, 614 
longer handling habituation period and greater statistical rigor. However, we do observe 615 
significant improvement in contextual fear memories in the inhibitor treated 16p11.2del mice. It 616 
is conceivable that the observed ventral hippocampal morphological rescue could explain the 617 
inhibitor effect on anxiety-like behaviors and contextual memory, given the established roles of 618 
these brain regions in emotional and stress coping responses (Kjelstrup et al., 2002; Bannerman 619 
et al., 2003; Maren and Holt, 2004; Adhikari et al., 2011).  620 
 The strongest effects we found were in olfaction and maternal behaviors, where we 621 
observed heightened responses in 16p11.2del mice, which were attenuated with inhibitor 622 
treatment. The decrease in latencies to retrieve pups and locate hidden food in the deletion mice 623 
may represent enhanced sensory perception or processing, but may also reflect changes to neural 624 
circuitry that govern motivational behavior.  625 
 Remarkably, we also report a partial rescue of the behavioral deficits by inhibitor 626 
treatment of adult mice. This effect is likely due to the fact that ERK dysregulation persists into 627 
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adulthood in the 16p11.2del animals (Pucilowska et al., 2015) and potentially disrupts the normal 628 
role of ERK signaling in synaptic plasticity. At the synapse ERKs promote regulation of 629 
translational mechanisms promoting protein synthesis and thus cognition (Thomas and Huganir, 630 
2004). These synaptic changes ultimately lead to refinement of neuronal connectivity. 631 
Furthermore, many mutations associated with ASDs converge on the ERK pathway impairing 632 
cognitive functioning and adaptive behavioral plasticity (Komiyama et al., 2002; Levitt and 633 
Campbell, 2009; Ebert and Greenberg, 2013). Correcting hyperactive ERK signaling in the adult 634 
16p11.2del mice may thus lead to ameliorating of behavioral phenotypes that are mediated by 635 
the post-natal functions of ERK signaling. Importantly, these data suggest that dysregulation of 636 
ERK activity can be rescued during brain development through restoration of normal cortical 637 
proliferation dynamics, and in adult mice, presumably due to the synaptic actions of the ERKs 638 
previously described in this mouse model (Tian et al., 2015; Lu et al., 2018).  639 
  We show that normalization of ERK signaling in the 16p11.2del mice can reverse the 640 
molecular and behavioral phenotypes in the 16p11.2del mice. While we observe significant 641 
effects on neuronal population sizes, our analysis was restricted to cortical neurons and, given 642 
that this is a germline hemideletion model, other areas of the nervous system are undoubtedly 643 
affected. This is further supported by our imaging analysis that shows multiple brain regions that 644 
are affected by the deletion. While we observe some behavioral improvements from post-natal 645 
treatment with the ERK/MAPK inhibitor, further analysis of changes to neuronal morphology 646 
and synaptic physiology in the 16p11.2del mice is warranted to help characterize the post-natal 647 
effects of the 16p11.2 deletion. Finally, we have only examined a few behavioral phenotypes and 648 
gender differences in behaviors were not examined. 649 
 In conclusion, our findings lead to three important conclusions. Our data strongly 650 
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supports the hypothesis that ASDs are neurodevelopmental disorders affecting global brain 651 
circuitry. Secondly, our work significantly strengthens the emerging hypothesis that multiple 652 
disorders of impaired cognition and ASDs converge onto a few fundamental pathways, such as 653 
the ERK/MAPK pathway, and affect a critical period of brain development. Finally, the 654 
cognitive and neuropsychiatric symptoms of 16p11.2 microdeletion disorder are amenable to 655 
targeted drug therapy, both during development and in the adult.  656 
 657 
 658 
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Figure Legends: 853 
 854 
 Fig. 1 Rescue of ERK activity with an ERK pathway inhibitor in 16p11.2del mice at E14.5 855 
and P10.  a) IHC of E14.5 coronal sections from mice treated with vehicle (veh) or ERK 856 
inhibitor (inh). Veh treated 16p11.2del mice shows upregulation of ERK activity in the 857 
dorsomedial cortex * (anti-pERK; green). This is abrogated after 5 days of inhibitor treatment 858 
starting at E10.5. (b) Western analysis of E14.5 veh or inh treated cortical lysates. (c) 859 
Quantification of Western analysis showing a significant increase in ERK1 and ERK2 activity in 860 
16p11.2del animals (pERK1, ****p<0.0001 and pERK2, *p<0.05), which is restored to normal 861 
level after inhibitor treatment ( ## p=0.0087; # p<0.05) (veh.treated: nWT = 19, nDel=13; 862 
inh.treated: nWT = 19, nDel=12). ERK1 total levels are decreased in vehicle deletion animals 863 
(**p<0.01) and inhibitor animals (****p<0.0001) (veh.treated: nWT = 8, nDel=7; inh.treated: 864 
nWT = 10, nDel=9) (d) Western analysis of P10 veh or inh treated cortical lysates (e) Western 865 
analysis of P10 veh or inh prenatally treated cortical lysates, quantified in (e) ERK1 and ERK2 866 
activity are elevated in deletion animals at P10 (pERK1 **p<0.01; pERK2, p**<0.01), which is 867 
normalized in embryonic inhibitor treatment (#p<0.05, ###p<0.001). All values normalized to 868 
loading control GAPDH or CoxIV and reported as a fold change. P values are from Bonferroni 869 
post-hoc analysis (* compares WT to deletion, # compares vehicle deletion to inhibitor deletion). 870 
 871 
Fig. 2 Reversal of deficits in cortical neurogenesis in the 16p11.2del mice after treatment 872 
with ERK pathway inhibitor at E14.5. Immunohistochemistry (IHC) of coronal sections and 873 
western analyses of cortical lysates at E14.5 (a) IHC with proliferation marker, BrdU injected 30 874 
min. prior to sacrifice. (a’) The number of BrdU+ progenitors was analyzed (veh.treated: nWT = 875 
8, nDel=6; inh.treated: nWT = 9, nDel=9); (*p<0.05, #p<0.05) . (b) IHC with intermediate 876 
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progenitor marker, Tbr2 (green). (b’) Quantification of Tbr2+ progenitors (veh. treated: nWT = 877 
11, nDel=4; inh.treated: nWT = 9, nDel=16) (**p<0.0012, ##p<0.0052). (b”) Quantification of 878 
western analysis (veh.treated: nWT = 29, nDel=37; inh.treated: nWT = 23, nDel=21), 879 
(****p<0.00001, #p<0.0388). (c) IHC for layer V marker, Ctip2 (red). (c’) Quantification of 880 
Ctip2+ neurons (veh. treated: nWT = 5, nDel=4; inh. treated: nWT = 4, nDel=6)(***p=0.0005, 881 
####p<0.0001, *p=0.026). (c”) Quantification of western analysis (veh treated: nWT=15, 882 
nDel=9; inh treated nWT= 8, nDel=11), (*p=0.0186, ##p=0.0073). (d) IHC with layer VI 883 
marker, Tbr1 (green). (d’) Quantification of Tbr1+ neurons (veh.treated: nWT = 9, nDel=9; 884 
inh.treated: nWT = 5, nDel=5) (*p=0.025, ###p=0.0004). (d”) Quantification of Western 885 
analysis (veh. treated: nWT=15, nDel=7; inh treated: nWT= 11, nDel=12) (*p=0.038, 886 
##p=0.0017). All western analyses data represented as a fold change, normalized to a loading 887 
control. P values are from Bonferroni post-hoc analysis (* compares WT to deletion, # compares 888 
vehicle deletion to inhibitor deletion). 889 
 890 
Fig. 3 Prenatal treatment with an ERK pathway inhibitor stably restores normal cortical 891 
cytoarchitecture 16p11.2del mice. (a) Mice were evaluated at P2 by IHC with layer II-IV 892 
marker Brn1, (green). (a’) Quantification of Brn1+ neurons shows a rescue in somatosensory 893 
cortex of 16p11.2del mice (veh treated: nWT=11, nDel=13; inh treated: nWT= 17, nDel=17) 894 
(*p<0.05). (b) IHC with layer 2-4 marker, Satb2 (red). (b’) Quantification of Satb2+ neurons. 895 
(veh treated: nWT=14, nDel=13; inh treated: nWT= 10, nDel=15) (*p=0.033, #p=0.0105). (c) 896 
IHC with layer V marker, Ctip2 (red). (c’) Quantification of Ctip2+ neurons (veh treated: 897 
nWT=21, nDel=14; inh treated: nWT= 9, nDel=13) (*p=0.014, #p=0.033). (d) IHC with layer VI 898 
marker, Tbr1+ (green). (d’) Quantification of Tbr1+ neurons (veh treated: nWT=8, nDel=9; inh 899 
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treated: nWT= 12, nDel=10) (**p=0.0076, #p=0.0535). P values are from Bonferroni post-hoc 900 
analysis (* compares WT to deletion, # compares vehicle deletion to inhibitor deletion). 901 
 902 
Fig. 4 Treatment with ERK pathway inhibitor normalizes the levels of the downstream 903 
ERK effectors: p27 Kip1 and cyclin D1. IHC of coronal sections and western analyses from WT 904 
and 16p11.2del mice at E14.5 (a) Immunostaining against CyclingD1 antibody (green), (a’) 905 
Western blot analysis, quantified in (a”) (veh treated: nWT=16, nDel=7; inh treated: nWT=16, 906 
nDel=13) (***p<0.001); (b) Immunostaining against p27Kip1(green), (b’) Western blot analysis, 907 
quantified in (b”) (veh treated: nWT=8, nDel=10; inh treated: nWT=8, nDel=10) (**p<0.01, 908 
*p<0.05). P values are from Bonferroni post-hoc analysis. 909 
 910 
Fig. 5 Prenatal ERK  inhibitor  treatment  partially  rescues  ventral  hippocampal  and  911 
lateral  septal  volume  in  16p11.2del mice. Mice were treated for 5 consecutive days starting 912 
at E10.5 and evaluated at P90. (a) TBM analyses revealed significant increased volume of SC, 913 
PAG and Hypo in 16p11.2del mice compared to WT littermates (t-test, p < 0.01 FWE cluster-914 
corrected, with cluster defining threshold of |t| > 2.3). In 16p11.2 deletion mice, we also 915 
observed an increased volume of the RS ctx, as well as reduced volume of vHPC, LS, Ent ctx 916 
and Amy (t-test, p < 0.01 FWE cluster-corrected, with cluster defining threshold of |t| > 2.3). (b) 917 
Comparison between treated and non-treated 16p11.2del mice shows that ERK-inhibitor 918 
produces bilateral foci of increased volume in the vHPC and LS (t-test, p < 0.01 FWE cluster-919 
corrected, with cluster defining threshold of |t| > 2.3). (c) A composite illustration of panels (a) 920 
and (b) revealed that foci of increased gray matter volume (red/yellow, from panel b) are 921 
spatially located in the same hippocampal and septal regions exhibiting reduced gray matter 922 
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volume in 16p11.2 del mice (blu/light blue, from panel a), suggesting a partial anatomical rescue 923 
of volumetric deficits upon treatment with ERK inhibitor. (d-e) Consistent with TBM results, 924 
anatomical labelling revealed reduced relative volume in vHPC (t-test: t17 = 3.78, p = 0.001) and 925 
LS (t-test: t17 = 2.21, p = 0.041) in 16p11.2del mice compared to WT littermates (one-way 926 
ANOVA of vHPC: F3,34 = 8.083, p < 0.001; one-way ANOVA of LS: F3,34 = 1.692, p = 0.1872). 927 
Treatment with ERK inhibitor in 16p11.2del mice partially restored morphoanatomical volume 928 
in these brain regions (vHPC, t-test: t16 = 2.79, p = 0.013), although the effects in LS did not 929 
reach full statistical significance (t-test, t16 = 1.78, p = 0.078). Amy, amygdala; Ent ctx, 930 
entorhinal cortex; Hypo, hypothalamus; LS, lateral septum; PAG, periaqueductal grey; RS, 931 
retrosplenial cortex; SC, superior colliculus; vHPC, ventral hippocampus. *p<0.05,**p<0.01. 932 
 933 
Fig. 6 Reversal of Behavioral Impairment of 16p11.2del mice after prenatal ERK pathway 934 
inhibitor treatment. WT or 16p11.2del -months old male or female mice treated with Veh or 935 
Inh at E10.5 for 5 days. (a) Elevated plus maze shows a no change in percentage of time in open 936 
arm, but decreased closed arm time in 16p11.2del mice that is rescued by inhibitor treatment 937 
(*p<0.05, #p<0.05) (veh treated: nWT=25, nDel=22; inh treated: nWT=27, nDel=28); (b) Open 938 
Field shows increased time spent in center in 16p11.2del mice that is rescued with inhibitor 939 
treatment (**p<0.01, #p<0.05) (veh treated: nWT=23, nDel=20; inh treated: nWT=19, nDel=18). 940 
(c) Fear conditioning shows increased freezing in 16p11.2del animals that improves with 941 
inhibitor treatment (**p<0.01) (veh treated: nWT=5, nDel=6; inh treated: nWT=11, nDel=11), 942 
cond. stimulus: 85 dB sound at 2800 Hz for 30 sec.; unconditioned stimulus (US: 0.56mA). 943 
Retention test performed 18 hrs later for 5 minutes in the absence of tone; (d) NOR was 944 
evaluated in WT and 16p11.2del animals (#p<0.05) (veh treated: nWT=16, nDel=12; inh treated: 945 
nWT=8, nDel=16); (e) Naïve females were exposed to 3 WT pups placed in 3 corner of the cage, 946 
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time to retrieve pups was recorded, (1st pup: **p<0.01; 2nd pup: **p<0.01; 3rd pup: 947 
***p=0.001) (veh treated: nWT=21, nDel=17; inh treated: nWT=6, nDel=6). (f) Mice were food 948 
deprived for 24 hours, then placed in a cage containing one food pellet (teddy graham) buried 949 
under normal cage bedding, time to retrieve was recorded (**p<0.01, ####p<0.0001) (veh 950 
treated: nWT=22, nDel=22; inh treated: nWT=22, nDel=7). P values are from Bonferroni post-951 
hoc analysis (* compares WT to deletion, # compares vehicle deletion to inhibitor deletion). 952 
 953 
Fig. 7 Postnatal treatment with ERK pathway inhibitor partially restores behavioral 954 
deficits in adult 16p11.2del mice. WT or 16p11.2del 3-months old male or female mice treated 955 
with Veh or Inh at P90 for 5 days. (a) Elevated plus maze analysis of percentage of time in open 956 
arm (*p<0.05), entries in open arm, immobility time (##p<0.01) and total distance traveled (veh 957 
treated: nWT=15, nDel=11; inh treated: nWT=12, nDel=7); (b) Open Field analysis of entries 958 
into center (##p<0.01), time spent in center and total distance traveled (veh treated: nWT=22, 959 
nDel=17; inh treated: nWT=23, nDel=9). (c) ELISA performed on whole brain lystaed of P90 960 
mice (** p<0.05; #p<0.05) (veh treated: nWT=10, nDel=8; inh treated: nWT=7, nDel=5).  (d) 961 
Mice were food deprived for 24 hours, then placed in a cage containing one food pellet (teddy 962 
graham) buried under normal cage bedding, time to retrieve (latency) was analyzed. P values are 963 
from Bonferroni post-hoc analysis (* compares WT to deletion, # compares vehicle deletion to 964 
inhibitor deletion). 965 







